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Background & Aim—Series studies have associated increased serum levels of ferritin with liver
fibrosis in patients with nonalcoholic fatty liver disease (NAFLD). We aimed to determine the
accuracy with which measurements of serum ferritin determine the presence and severity of liver
fibrosis, and whether combining noninvasive scoring systems with serum ferritin analysis
increases the accuracy of diagnosis of advanced liver fibrosis.
Methods—We performed a retrospective analysis of data from 1014 patients with liver biopsy-
confirmed NAFLD. Three cut-points of serum ferritin level, adjusted for sex, were established
based on receiver operating characteristics curve analysis: 1.0 (the upper limit of normal [ULN]),
1.5-fold ULN, and 2.0-fold ULN. Three multiple logistic regression models were created to
determine the association of these cutoff values with liver fibrosis, adjusting for age, sex, race,
diabetes, body mass index, and level of alanine aminotransferase.
Results—A greater proportion of patients with increased serum levels of ferritin had definitive
NASH and more-advanced fibrosis than patients without increased levels. In all models, serum
level of ferritin was significantly associated with the presence and severity of liver fibrosis.
However, for all 3 cutoff values, area under the receiver operating characteristic curve values were
low (less than 0.60) for the presence of fibrosis or any stage of liver fibrosis; ferritin level
identified patients with fibrosis with 16%–41% sensitivity and 70%–92% specificity. The
accuracy with which noninvasive scoring systems identified patients with advanced fibrosis did
not change with inclusion of serum ferritin values.
Conclusions—Although serum levels of ferritin correlate with more-severe liver fibrosis, based
on adjusted multiple logistic regression analysis, serum ferritin levels alone have a low level of
diagnostic accuracy for the presence or severity of liver fibrosis in patients with NAFLD.
Keywords
iron; ROC; BMI; ALT; cirrhosis
Serum ferritin is routinely measured in patients with nonalcoholic fatty liver disease
(NAFLD) as part of the laboratory work-up to rule out other causes of liver disease. Ferritin
levels are often elevated in patients with NAFLD with early large series [1,2] reporting
increased ferritin in about a half of NAFLD patients. The relationship of serum ferritin with
severity of liver disease in NAFLD has been examined in several studies. The largest series
found a significant association of ferritin levels with presence and severity of nonalcoholic
steatohepatitis (NASH) and liver fibrosis [3–9]. For instance, a large Italian series [8]
reported a 1.67-fold greater likelihood for advanced fibrosis in patients with NAFLD with
increased serum ferritin levels; similarly, in a recent American series [9], a serum ferritin
level above 1.5 times the upper limit of normal was associated with a 1.66-fold higher
likelihood of having advanced fibrosis.
Based on this, it has been proposed that serum ferritin levels could potentially be used to
predict presence and severity of liver fibrosis in patients with NAFLD. However, the
evidence associating elevated serum ferritin with severity of liver fibrosis in NAFLD comes,
at the best, from the results of multiple logistic regression analyses. The accuracy of serum
ferritin levels in diagnosing presence and severity of liver fibrosis has not been formally
evaluated; furthermore, it remains uncertain whether adding serum ferritin levels to the
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several non-invasive scoring systems used routinely in predicting the severity of liver
fibrosis increases the accuracy of the scoring systems. To deal with these issues we analyzed
a large database of patients with well-characterized and liver biopsy-confirmed NAFLD to
1) determine the accuracy of serum ferritin levels in identifying presence and severity of
liver fibrosis, and 2) to determine whether the accuracy of several non-invasive scoring
systems increases in identifying advanced liver fibrosis by adding serum ferritin levels.
PATIENTS AND METHODS
This is an international, retrospective cohort study of 1,014 patients with well-characterized
and liver biopsy-confirmed NAFLD. They were untreated, consecutively biopsied patients
that came from one of the following four medical institutions: Newcastle University, United
Kingdom, University of Sydney, Australia, University of Torino, Italy, and University of
Kentucky, United States. Inclusion criteria was the diagnosis of NAFLD confirmed by liver
biopsy, and the liver biopsy represents the reference standard. Liver biopsies were done
regardless of the ferritin level or fibrosis scores. Exclusion criteria was a liver disease of
other etiology such as alcohol-induced or drug-induced liver disease, autoimmune or viral
hepatitis, and cholestatic or metabolic/genetic liver disease. These other liver diseases were
excluded using specific clinical, laboratory, radiographic, and/or histological criteria. All
patients had a negative history of alcohol abuse as indicated by a weekly ethanol
consumption of <140 g in women, and <210 g in men. History of alcohol consumption was
specifically investigated by interviewing the patients and in many cases also by interviewing
close relatives during both the first and follow-up visits.
Extensive clinical and laboratory data were collected within seven days of the liver biopsy
procedure. The ethnicity and race were determined based on the categories proposed by the
United States Department of Health and Human Services Public Health Service [10]. Body
mass index (BMI) and waist circumference were measured. Laboratory evaluation included
routine liver biochemistry; complete blood count; lipid profile; fasting glucose; fasting
insulin; iron studies (serum iron, serum ferritin, serum transferrin, transferrin saturation,
total iron-binding capacity [TIBC]); HFE gene mutation; viral serology for hepatitis B and C
infection; autoantibodies; alpha 1 antitrypsin levels and phenotype; and ceruloplasmin
levels. The degree of insulin resistance was determined by the homeostatic model
assessment (HOMA) [11]. Components of the metabolic syndrome [12] were recorded
including central obesity, hyperglycemia or previously diagnosed type 2 diabetes,
hypertriglyceridemia, hypertension, and low HDL-cholesterol. The presence of diabetes
mellitus (fasting glucose ≥126 mg/dL or treatment with antidiabetic drugs), obesity (BMI
≥30 kg/m2, or ≥25 kg/m2 in Asians), and overweight (BMI 25–29.9 kg/m2, or 23–24.9
kg/m2 in Asians) was also recorded.
Serum ferritin levels were measured by enzyme-linked immunosorbent assays (ELISA) or
enzyme immunoassays as recommended by the World Health Organization [13]. The upper
limit of normal (ULN) for serum ferritin used for comparisons was adopted from the
hemochromatosis and iron overload screening study, that is, 300 ng/mL in men and 200
ng/mL in women [14].
Angulo et al. Page 3
Clin Gastroenterol Hepatol. Author manuscript; available in PMC 2015 July 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Four validated non-invasive scoring systems originally created to distinguish between
patients with and without advanced (stage 3–4) fibrosis were calculated using the original
reported formulas [15–18]. They were the NAFLD fibrosis score, formula:
 ; the AST/
platelet ratio index, formula: ; the FIB-4 score,
formula:  ; the BARD score,
scale 0–4: BMI ≥ 28 kg/m2 = 1 point, AST to ALT ratio ≥ 0.8 = 2 points; diabetes mellitus =
1 point. The values for the ULN for AST were set according to the International Federation
of Clinical Chemistry, that is, 35 U/L for men, and 30 U/L for women. The ULN for ALT
was 19 U/L in women, and 30 U/L in men [19].
Liver Histology
Liver biopsies were routinely stained with hematoxylin and eosin, Masson’s trichrome, and
special stains for iron and copper. Liver biopsies were read by a single liver pathologist in
each participating center who was not always blind to laboratory tests results including
ferritin levels. The stage of fibrosis was scored based on a 5-point scale as proposed [20].
Briefly, stage 0 = absence of fibrosis; stage 1 = perisinusoidal or portal; stage 2 =
perisinusoidal and portal/periportal; stage 3 = septal or bridging fibrosis; and stage 4 =
cirrhosis. Advanced fibrosis was defined as stage 3–4 fibrosis. The grade of steatosis,
inflammation and cellular ballooning were scored as proposed [20]. Presence of NASH was
also recorded and categorized as definitive, borderline/suspicious, or no NASH based on
pattern and distribution of liver histological lesions as proposed [21]. Semiquantitative
grading (0 – 3+) of hepatic iron staining using Perls’ iron stain was recorded. To control for
biopsy size, the length of the biopsy was measured with a hand ruler, and the number of
portal areas on one cross-section was counted. The mean (±SD) length of the liver biopsy
was 19 ± 8.5 mm (median 18 mm, interquartile range 15, 25). The number of portal areas
was 11 ± 4.5 (median 10, interquartile range 7, 16).
Statistical Analysis
Baseline characteristics were compared by ferritin level status (normal vs. elevated) using a t
test or ANOVA test when appropriate for continuous variables or a Chi-squared test for
categorical variables. Standard non parametric tests were used to analyze variables without a
normal distribution. The independent association of serum ferritin levels with increased liver
fibrosis was evaluated by multiple logistic regression analysis using the forward stepwise
selection method with a p value < 0.1 chosen for variable selection. First, we determined the
area under the receiver operating characteristic (ROC) curves of serum ferritin to identify
the most accurate cut-off of ferritin to distinguish between patients with and without
advanced (stage 3–4) fibrosis. The most accurate cut-off points were ferritin from 1.0 x
ULN to 1.7 x ULN. For these cut-offs, the sensitivity − (1−specificity) varied from 0.11 to
0.12. Thus, any cut-off value of ferritin from 1.0 to 1.7 x ULN would essentially provide the
same results. For the purpose of simplicity for potential readers and in order to be able to
compare the results of our study with prior similar studies [8,9,14] we established three
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multiple logistic regression models with each of the three dichotomized levels: 1.0, 1.5 and
2.0 x ULN which represent the most accurate range of ferritin cut-off points to distinguish
between patients with and without increased or advanced fibrosis. The association of serum
ferritin levels with liver fibrosis was adjusted by the following variables selected a priori
and included in each multiple logistic regression model: age, sex, race, BMI, diabetes, ALT
and site. The diagnostic accuracy of these three cut-points of serum ferritin to distinguish
between patients with and without increased or advanced fibrosis was investigated by
determining the area under the ROC curves, sensitivity and specificity. Subsequently, we
used ROC curves analysis to determine the effect size of serum ferritin values when added
to simple noninvasive scoring systems [15–18] to distinguish between patients with and
without advanced liver fibrosis. Ferritin was tested in models including composite variables
of score and not the score itself. This was done to determine the independent value of ferritin
(i.e., the additive variable) without having fixed regression coefficients of the other
variables. All tests were two-tailed and a p value < 0.05 was considered to indicate statistical
significance. Statistical analyses were performed using IBM SPSS Statistics version 21, and
SigmaPlot 12.3 software. The study was approved by appropriate regulatory bodies at all
centers.
RESULTS
Baseline characteristics
Patients were recruited from 2003 to 2011. There were no adverse events related to the
reference standard (liver biopsy) or index test (ferritin measurement). The prevalence of
serum ferritin >ULN was 33% [331/1,014 (189 men vs. 142 women, p = 0.8)], >1.5-fold
ULN was 19% [189/1,014 (106 men vs. 83 women, p = 0.6)], and >2-fold ULN was 10%
[103/1,014 (55 men vs. 48 women, p = 0.3)]. The comparison of patient with normal and
elevated serum ferritin levels is described in Table 1. Patients with elevated serum ferritin
levels were more likely to have the histological diagnosis of definitive NASH (45.9% vs.
34.8%, respectively, p < 0.001), and advanced (stage 3–4) liver fibrosis (33.3% vs. 23.5%
respectively, p = 0.001) (Table 1; Figure 1).
Serum ferritin levels adjusted by sex did not differ significantly between patients who
suffered from the metabolic syndrome and those who did not (p = 0.18), or among number
(0 to 5) of components of the metabolic syndrome (p = 0.14). There was no a significant
difference in the proportion of patients carrying one or two HFE gene mutations between
patients with normal or elevated serum ferritin. Patients with elevated serum ferritin had
more hepatic iron as indicated by a positive Perls’ staining (57% vs. 26% respectively, p <
0.001); and Perls’ staining intensity was significantly greater in patients with definitive
NASH (p = 0.04). The amount of hepatic iron as indicated by Perls’ staining was not
significantly different between patients with or without liver fibrosis (p = 0.9) or among the
different stages of fibrosis (p = 0.2).
Association of serum ferritin with liver fibrosis
By multiple logistic regression the three cut-points of elevated serum ferritin levels
increased the likelihood of having increased liver fibrosis, significant fibrosis, or advanced
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fibrosis. The odds ratio progressively increased as the serum ferritin cut-point increased for
either presence of fibrosis or severity of fibrosis (Table 2).
Diagnostic accuracy of serum ferritin levels
The overall accuracy of serum ferritin levels to diagnose any stage or combination of stages
of liver fibrosis was rather poor as indicated by an area under the ROC curves below 0.60
for any serum ferritin cut-point analyzed (Table 3). Similarly, the sensitivity of these serum
ferritin cut-points was low and between 13% and 41% whereas the specificity was 70% to
95% (Table 3). Additional ROC curves were created considering serum ferritin as
continuous variable and ordinal variable; the area under the ROC curves were equally poor
and less than 0.60 similar to when considering ferritin as a binary variable (data not shown).
Table 4 shows the area under the ROC curve to distinguish between patients with and
without advanced (stage 3–4) fibrosis for the four noninvasive scoring systems alone and
when combined with elevated serum ferritin. The accuracy of these scoring systems
remained essentially the same when serum ferritin values were added. Supplemental Figure
1 illustrates the area under the ROC curves for these four scoring systems alone and the
three cut-points alone of serum ferritin to distinguish between patients with and without
advanced (stage 3–4) fibrosis. When serum ferritin levels were used to reclassify patients
that were in the indeterminate range based on the NAFLD fibrosis score, APRI and FIB-4
score, the proportion of patients that would be correctly reclassified was pretty similar to the
proportion of patients that would be erroneously reclassified (data not shown).
Serum ferritin levels had a similarly poor accuracy as ALT levels in the diagnosis of
definitive NASH as indicated by an area under the ROC curve of 0.58 (95% CI 0.54, 0.61)
and 0.60 (95% CI 0.56, 0.64), respectively (Supplemental Figure 2).
DISCUSSION
Our study shows that similar to some prior publications [3,7–9], increased serum ferritin
levels are associated with the presence of liver fibrosis and with more advanced liver
fibrosis in patients with NAFLD. Our study, however, extends our current knowledge on the
association of ferritin and liver fibrosis, and shows that: 1) serum ferritin levels on its own
lack overall accuracy to distinguish between patients with NAFLD with and without liver
fibrosis and to distinguish between patients with or without severe or advanced liver
fibrosis. This is indicated by an area under the ROC curves less than 0.60, and sensitivity
values between 13% and 41% for any cut-point of elevated serum ferritin. 2) The overall
accuracy of several non-invasive scoring systems in distinguishing between patients with
and without advanced fibrosis does not significantly change by adding the serum ferritin
levels. Therefore, elevated serum ferritin levels in patients with NAFLD cannot be used to
accurately predict presence or severity of liver fibrosis or in making decisions regarding the
need for a liver biopsy for fibrosis staging. 3) An additional important finding of our study is
the relatively high specificity of increased serum ferritin to rule out the presence and
severity of liver fibrosis, with specificity values between 76% and 95% to rule out presence
(stage 1–4) of fibrosis, 72% to 93% to rule out significant (stage 2–4) fibrosis, and 70% to
92% to rule out presence of advanced (stage 3–4) fibrosis (Table 3).
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Ferritin is an acute-phase protein that can be induced in the setting of systemic
inflammation, and thus, is often elevated in conditions associated with chronic inflammation
such as obesity, diabetes, and metabolic syndrome [22]. Serum ferritin levels are often
elevated in the setting of chronic alcoholism and in chronic liver diseases such as hepatitis C
infection and alcohol-induced liver disease [23,24]. Ferritin is the primary tissue iron-
storage protein and thus its expression increases in conditions associated with iron overload
resulting in increased ferritin levels in both tissue and circulation. Some evidence suggests
an association between increased serum ferritin and mild iron overload, unrelated to
hereditary hemochromatosis, in conditions associated to the metabolic syndrome including
NAFLD [22,25,26]. The association of hyperferritinemia and increased hepatic iron has
been demonstrated in studies quantifying hepatic iron though liver biopsy, radiological
images, and quantitative phlebotomies [25,27–29]. However, several other series of patients
with NAFLD had not found an association of serum ferritin levels with increased hepatic
iron [1,2,30]; further, a recent controlled trial reported no association of iron depletion
achieved by phlebotomies with improvement in liver enzymes, insulin sensitivity or amount
of steatosis in patients with NAFLD [31]. Also, recent cross-sectional large series had
reported increased hepatic iron accumulation associated with more advanced liver fibrosis in
NAFLD [25,26], but it remains uncertain whether the increased iron deposition is a cause or
a consequence of increased liver fibrosis. We found an association of increased hepatic iron
accumulation and the presence of definitive NASH but not with presence and severity of
fibrosis stage in our patients.
In summary, this large series reproduces prior data demonstrating a significant association of
increased serum ferritin with severity of liver fibrosis based on the results of multiple
logistic regression analyses. However, our study goes beyond and expands prior data
demonstrating that serum ferritin values on its own cannot be used to make the diagnosis of
presence or severity of liver fibrosis, although normal serum ferritin, or less elevated levels
may reasonably exclude presence and severity of liver fibrosis. In addition, our study
demonstrates that the accuracy of several noninvasive scoring systems to distinguish
between patients with and without advanced fibrosis does not increase by adding serum
ferritin levels.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
Funding source: This study was supported by a National Institute of Health R01 DK82426 grant (to P. Angulo),
and The European Community’s Seventh Framework Programme (FP7/2007–2013) under grant agreement n°
HEALTH-F2-2009-241762 for the project FLIP (to E. Bugianesi). JG is supported by grants from the Sydney
Medical Foundation and grants from the NHMRC (632630 and 1049857). These sponsors played no role in the
study design or the collection, analysis, and interpretation of data.
Abbreviations
NAFLD nonalcoholic fatty liver disease
Angulo et al. Page 7
Clin Gastroenterol Hepatol. Author manuscript; available in PMC 2015 July 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
NASH nonalcoholic steatohepatitis
ALT alanine aminotransferases
AST aspartate aminotransferases
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FIGURE 1.
Boxplot illustration of the relationship of serum ferritin levels and fibrosis stage in women
(p = 0.003) and men (p < 0.001).
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Table 1
Clinical and demographic characteristics of the patient population
Variable Total (n = 1,014) Ferritin level P value
Normal (n = 683) Elevated (n = 331)
Age (years) 46.9 ± 0.4 46.5 ± 0.5 47.6 ± 0.7 0.2
Gender
 Female 428 286 (42%) 142 (43%) 0.8
 Male 586 397 (58%) 189 (57%)
Ethnic group
 Hispanic 6 4 (0.6%) 2 (0.6%) 0.97
 Non-Hispanic 1,008 679 (99.4%) 329 (99.4%)
Race group 0.002
 White 929 641 (93.9%) 288 (87%)
 Asian 61 29 (4.2%) 32 (9.7%)
 Black, or African American 7 5 (0.7%) 2 (0.6%)
 American Indian/Alaska Native 2 0 (0%) 2 (0.6%)
 Native Hawaiian or Other Pacific Islander 15 8 (1.2%) 7 (2.1%)
Body mass index (kg/m2) 31.3 ± 0.2 31.6 ± 0.2 30.9 ± 0.3 0.09
BMI category 0.2
 Normal 111 76 (11.1%) 35 (10.6%)
 Overweight 333 229 (33.5%) 104 (31.4%)
 Obese 570 378 (53.3%) 192 (58%)
Waist circumference (cm) 100.9 ± 0.5 102 ± 0.6 99 ± 0.8 0.02
Central obesity (yes) 599 431 (63%) 168 (51%) 0.2
Diabetes (yes) 298 188 (27.5%) 110 (33.2%) 0.07
Hypertension (yes) 363 231 (33.8%) 132 (39.9%) 0.06
Hypertriglyceridemia (yes) 542 361 (52.9%) 181 (54.7%) 0.6
Hypercholesterolemia (yes) 447 308 (45.1%) 139 (42%) 0.4
Low-HDL cholesterol (yes) 413 264 (38.7%) 149 (45%) 0.05
Metabolic syndrome (yes) 384 258 (37.8%) 126 (38%) 0.2
ALT (IU/L) 81 ± 2 72 ± 2 101 ± 4 < 0.001
AST (IU/L) 55 ± 1 47 ± 1 70 ± 3 < 0.001
AST/ALT ratio 0.8 ± .02 0.7 ± 0.02 0.8 ± 0.05 0.1
Total bilirubin (mg/dL) 0.9 ± 0.03 0.8 ± 0.02 0.9 ± 0.05 0.04
Albumin (g/dL) 4.4 ± 0.02 4.4 ± 0.02 4.4 ± 0.03 0.2
Alkaline phosphatase (IU/L) 128 ± 3 125 ± 3 134 ± 5 0.1
GGT (IU/L) 103 ± 5 100 ± 5 110 ± 10 0.3
Platelet (×109) 237 ± 3 240 ± 3 231 ± 5 0.1
Glucose (mg/dL) 114 ± 2 115 ± 3 210 ± 2 0.6
Insulin (μIU/L) 19 ± 1 19 ± 1 21 ± 2 0.3
HOMA 5 ± 0.2 4.7 ± 0.2 5.5 ± 0.4 0.05
Triglycerides (mg/dL) 194 ± 4 193 ± 5 196 ± 8 0.7
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Variable Total (n = 1,014) Ferritin level P value
Normal (n = 683) Elevated (n = 331)
Total Cholesterol (mg/dL) 209 ± 2 210 ± 2 209 ± 3 0.7
HDL-cholesterol (mg/dL) 46 ± 0.4 46 ± 1 45 ± 1 0.4
LDL-cholesterol (mg/dL) 139 ± 2 142 ± 2 133 ± 3 0.03
Iron (μg/dL) 102 ± 2 95 ± 3 114 ± 3 < 0.001
Ferritin (ng/mL) 252 ± 8 122 ± 3 521 ± 17 < 0.001
Transferrin (mg/dL) 274 ± 3 285 ± 4 258 ± 4 < 0.001
TIBC (μg/dL) 316 ± 3 320 ± 3 309 ± 4 < 0.04
Transferrin saturation (%) 29 ± 0.5 26 ± 1 34 ± 1 < 0.001
HFE gene mutation 704 0.99
 WT/WT 492 300 (43.9%) 192 (58%)
 C282Y/WT 54 32 (4.7%) 22 (6.6%)
 H63D/WT 128 82 (12%) 46 (13.9%)
 H63D/H63D 20 12 (1.8%) 8 (2.4%)
 C282Y/H63D 10 6 (0.9%) 4 (1.2%)
NASH category 0.003
 No NASH 495 353 (51.7%) 142 (42.9%)
 Suspicious/borderline 129 92 (13.5%) 37 (11.2%)
 Definitive 390 238 (34.8%) 152 (45.9%)
Fibrosis stage < 0.001
  0 351 267 (39.1%) 84 (25.4%)
  1 251 165 (24.2%) 86 (26%)
  2 141 90 (13.2%) 51 (15.4%)
  3 161 85 (12.4%) 76 (23%)
  4 110 76 (11.1%) 34 (10.3%)
Data are presented as mean ± standard error, or number (proportion)of patients with a condition. ALT, alanine aminotransferases; AST, aspartate
aminotransferases; GGT, gamma-glutamyl transferase; HOMA, homeostatic model assessment; HDL, high density lipoprotein; LDL, low density
lipoprotein; TIBC, total iron-binding capacity; NASH, nonalcoholic steatohepatitis.
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